UNSPSC 51101903: Primaquine

This classification denotes an antimalarial agent with the molecular formula C15H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MVR3634GX1, chemically known as 1,4-pentanediamine, n4-(6-methoxy-8-quinolinyl)- (9ci) but generally known as primaquine, which bears US NIH Compound Identifier 4908. European Medicines Agency schedules Primaquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10043MIG. The term PRIMAQUINE is an International Non-Proprietary Name.

UNSPSC 51101903 Primaquine is a Commodity code for pharmaceutical antimalarial agents; however, the recent state and local contract activity tagged under this code does not align with primaquine procurement. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets—neither of which is primaquine—while Seminole County, Florida issued an IFB in June 2026 for Naloxone and Safe Drug Deactivation Systems, which are opioid-reversal agents and harm-reduction supplies unrelated to antimalarial treatment. The issuing bodies include state health departments and county public health divisions using cooperative purchasing vehicles and competitive bidding. This code shows little relevant recent activity aligned with its nominal scope.

Opportunities under this code remain concentrated in Florida and Illinois. The Illinois procurement, IFB 26482DPHPREPDB53392, closed September 11, 2026, and resulted in a completed $2,999,999.11 contract award over three years including renewals with an initial 12-month term. Seminole County's IFB 60459723LAS, posted June 30, 2026, sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems for annual delivery with a two-year initial term and one-year renewal option. Vendors were required to submit bids electronically with all shipping costs included. Neither opportunity demonstrates active procurement demand aligned with primaquine's pharmaceutical classification within state and local health systems.